AB Science Secures Debt Repayment Extension and Financial Stability
AB Science announced on Monday a definitive agreement with all its financial creditors regarding the postponement of its debt repayment deadlines. This agreement follows a negotiation period during which a standstill was granted by the creditors.
The company has reached a unanimous agreement with its creditors on the following terms: a 24-month postponement of its bank debt repayment (total amount of approximately 3.7 million euros) and a 12-month postponement of the repayment of a loan taken from the EIB (total principal amount of 12 million euros, initially repayable in January and December 2028). Additionally, the contract stipulating the repayment of support provided by Bpifrance for the ROMANE research project in the event of commercial success of masitinib in neurology, has also been restructured.
Extended Financing Capacity
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Given this agreement and its current cash position, AB Science states that it can fund its operations beyond the next 12 months. The company also postpones the publication of its annual report to no later than May 13, 2026.
SectorSanté · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
